保护大脑:Nrf2-ARE途径作为的治疗重点
Arshdeep Kaur1, Navpreet Kaur1, Shamsher Singh2
1Department of Pharmacy Practice, ISF College of Pharmacy (An Autonomous College), Moga-142001, Punjab, India.
Central nervous system agents in medicinal chemistry
|August 28, 2025
概括
,特别是叶,涉及氧化应激. 针对Nrf2通路可以通过减少氧化损伤和改善患者的神经元生存来提供新的治疗方法.
科学领域:
- 神经科学
- 细胞生物学
- 病理生理学
背景情况:
- 全球有6500万人患有,
- 时间叶 (TLE) 是一种焦点性,在30%的患者中,尽管服用药物,症状仍持续.
- 由活性氧物种 (ROS) 驱动的氧化应激 (OS) 是发育和神经元损伤的关键.
研究的目的:
- 探索氧化应激在中的作用.
- 研究 Nrf2 途径作为治疗的潜力.
主要方法:
- 关于氧化应激和的最新研究.
- 对 Nrf2 抗氧化反应元素 (ARE) 信号通路在细胞防御中的作用的分析.
- 对治疗的Nrf2激活化合物的研究进行审查.
主要成果:
- 氧化应激和ROS过度产生导致神经元功能障碍和死亡.
- Nrf2 是细胞抗氧化防御的关键调节者.
- 激活Nrf2通路可以增强抗氧化剂的表达并保护神经元.
结论:
- 针对Nrf2是一种有前途的治疗策略.
- Nrf2的激活可能会降低神经系统的活力,并改善的神经元存活率.
- 开发Nrf2激活化合物可能会导致新的抗疗法.
相关概念视频
Antiepileptic Drugs: GABAergic Pathway Potentiators
635
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
635
Epilepsy and Seizures: Overview
275
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
275
NF-κB-dependent Signaling Pathway
7.8K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.8K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
445
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
445
Antiepileptic Drugs: Glutamate Antagonists
511
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
511
Antiepileptic Drugs: Potassium Channel Activators
274
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
274


